No Data
No Data
Zai Lab Limited (NASDAQ:ZLAB) Institutional Owners May Be Pleased With Recent Gains After 25% Loss Over the Past Year
Zai Lab Limited's (NASDAQ:ZLAB) Prospects Need A Boost To Lift Shares
Zai Lab Limited to Approve Interim Financial Results
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Haitong Int'l: maintains a "outperform" rating on Zai Lab (09688) with a target price lowered to HKD 65.76.
According to Haitong, driven by the sales of Agamode and three other potential blockbuster products, the company is expected to achieve a revenue growth of around 50% CAGR during 2023-2028.
Zai Lab Rewards Employees With Equity Incentive